{"id":3706,"date":"2021-04-08T17:03:05","date_gmt":"2021-04-08T21:03:05","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/"},"modified":"2026-09-24T00:07:21","modified_gmt":"2026-09-24T04:07:21","slug":"gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/","title":{"rendered":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020"},"content":{"rendered":"\n<strong>Paris, France, le 8 avril 2021, 19h00 CET<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir d\u00e9pos\u00e9 son document d\u2019enregistrement universel (URD) 2020 en langue anglaise aupr\u00e8s de l\u2019Autorit\u00e9 des March\u00e9s Financiers (AMF) sous le num\u00e9ro D.21-0276.\n\n&nbsp;\n\nLe document d\u2019enregistrement universel inclut notamment :\n<ul>\n \t<li>le rapport financier annuel 2020 ;<\/li>\n \t<li>le rapport de gestion\u00a0;<\/li>\n \t<li>le rapport sur le gouvernement d\u2019entreprise ; et<\/li>\n \t<li>le descriptif du programme de rachat d\u2019actions.<\/li>\n<\/ul>\n&nbsp;\n\nCe document d\u2019enregistrement universel peut \u00eatre consult\u00e9 sur le site internet de la Soci\u00e9t\u00e9 (www.gensight-biologics.com), section Investisseurs, et sur le site de l\u2019AMF (www.amf-france.org).\n\n&nbsp;\n<h3><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il. D\u00e9velopp\u00e9 dans le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), le principal produit candidat de GenSight Biologics, LUMEVOQ<sup>\u00ae<\/sup> (GS010 ; lenadogene nolparvovec), est actuellement en cours d&rsquo;examen pour enregistrement en Europe, et en phase III pr\u00e9alablement au d\u00e9p\u00f4t de la demande d\u2019autorisation de mise sur le march\u00e9 aux Etats-Unis (<em>Biologics License Application<\/em> [BLA]).\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 8 avril 2021, 19h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir d\u00e9pos\u00e9 son document d\u2019enregistrement universel (URD) 2020 [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76,80],"post-year":[],"class_list":["post-3706","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 8 avril 2021, 19h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir d\u00e9pos\u00e9 son document d\u2019enregistrement universel (URD) 2020 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T21:03:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:21+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020\",\"datePublished\":\"2021-04-08T21:03:05+00:00\",\"dateModified\":\"2026-09-24T04:07:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/\"},\"wordCount\":353,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/\",\"name\":\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-04-08T21:03:05+00:00\",\"dateModified\":\"2026-09-24T04:07:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/04\\\/08\\\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020 - GenSight Biologics","og_description":"Paris, France, le 8 avril 2021, 19h00 CET \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir d\u00e9pos\u00e9 son document d\u2019enregistrement universel (URD) 2020 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/","og_site_name":"GenSight Biologics","article_published_time":"2021-04-08T21:03:05+00:00","article_modified_time":"2026-09-24T04:07:21+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020","datePublished":"2021-04-08T21:03:05+00:00","dateModified":"2026-09-24T04:07:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/"},"wordCount":353,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/","name":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2021-04-08T21:03:05+00:00","dateModified":"2026-09-24T04:07:21+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/04\/08\/gensight-biologics-met-a-disposition-son-document-denregistrement-universel-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics met \u00e0 disposition son Document d\u2019Enregistrement Universel 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3706"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3706\/revisions"}],"predecessor-version":[{"id":6726,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3706\/revisions\/6726"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3706"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3706"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3706"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3706"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}